JP2023538118A5 - - Google Patents

Info

Publication number
JP2023538118A5
JP2023538118A5 JP2023512389A JP2023512389A JP2023538118A5 JP 2023538118 A5 JP2023538118 A5 JP 2023538118A5 JP 2023512389 A JP2023512389 A JP 2023512389A JP 2023512389 A JP2023512389 A JP 2023512389A JP 2023538118 A5 JP2023538118 A5 JP 2023538118A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
sequence
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538118A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/046994 external-priority patent/WO2022040586A2/en
Publication of JP2023538118A publication Critical patent/JP2023538118A/ja
Publication of JP2023538118A5 publication Critical patent/JP2023538118A5/ja
Pending legal-status Critical Current

Links

JP2023512389A 2020-08-21 2021-08-20 Car発現細胞のインビボ生成のための組成物及び方法 Pending JP2023538118A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063068876P 2020-08-21 2020-08-21
US63/068,876 2020-08-21
US202163154609P 2021-02-26 2021-02-26
US63/154,609 2021-02-26
PCT/US2021/046994 WO2022040586A2 (en) 2020-08-21 2021-08-20 Compositions and methods for in vivo generation of car expressing cells

Publications (2)

Publication Number Publication Date
JP2023538118A JP2023538118A (ja) 2023-09-06
JP2023538118A5 true JP2023538118A5 (cg-RX-API-DMAC7.html) 2024-08-27

Family

ID=78000765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512389A Pending JP2023538118A (ja) 2020-08-21 2021-08-20 Car発現細胞のインビボ生成のための組成物及び方法

Country Status (11)

Country Link
US (1) US20230302155A1 (cg-RX-API-DMAC7.html)
EP (1) EP4199960A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023538118A (cg-RX-API-DMAC7.html)
KR (1) KR20230058427A (cg-RX-API-DMAC7.html)
AU (1) AU2021329404A1 (cg-RX-API-DMAC7.html)
CA (1) CA3188978A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023000495A1 (cg-RX-API-DMAC7.html)
IL (1) IL300489A (cg-RX-API-DMAC7.html)
MX (1) MX2023002107A (cg-RX-API-DMAC7.html)
TW (1) TW202227124A (cg-RX-API-DMAC7.html)
WO (1) WO2022040586A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3097117B1 (en) 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
SI3844267T1 (sl) 2018-08-31 2025-10-30 Novartis Ag Postopki izdelave celic, ki izražajo receptorje himernega antigena
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
JP7805928B2 (ja) 2019-11-26 2026-01-26 ノバルティス アーゲー Cd19及びcd22キメラ抗原受容体及びその使用
WO2022097065A2 (en) * 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
EP4388000A1 (en) * 2021-08-20 2024-06-26 Novartis AG Methods of making chimeric antigen receptor?expressing cells
KR20250067174A (ko) 2022-09-15 2025-05-14 노파르티스 아게 키메라 항원 수용체 요법을 사용한 자가면역 장애의 치료
JP2026519263A (ja) 2022-10-26 2026-06-15 ノバルティス アーゲー レンチウイルス製剤
WO2026034653A1 (ko) * 2024-08-05 2026-02-12 동국대학교 산학협력단 Cd44를 포함하는 암세포를 선택적으로 사멸하고, 사멸 효율성을 향상시키기 위한 고분자 화합물 및 그 제조 방법
IL324785A (en) * 2023-06-07 2026-01-01 Synthekine Inc Modified immunoglobulin variable heavy domains having reduced immunogenicity

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HK1043608B (en) 1999-08-17 2007-12-07 Biogen Ma Inc. Baff receptor (bcma), an immunoregulatory agent
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
EP2514718A4 (en) 2009-12-18 2013-09-04 Kao Corp METHOD FOR PRODUCING MESOPOROUS SILICONE ARTICLES
JP5603063B2 (ja) 2009-12-21 2014-10-08 花王株式会社 複合シリカ粒子の製造方法
RU2012141952A (ru) 2010-03-02 2014-04-10 Кинг Абдулла Юнивесити Ов Сайенс Энд Текнолэджи Наночастицы волокон оксида кремния с развитой поверхностью
US20130052117A1 (en) 2010-03-04 2013-02-28 Keio University Process for producing porous silica, and porous silica
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
US20130145488A1 (en) 2011-12-06 2013-06-06 Iowa State University Research Foundation, Inc. Mesoporous silica nanoparticles suitable for co-delivery
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
ES2773895T3 (es) 2012-04-16 2020-07-15 Harvard College Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
IN2014MN02293A (cg-RX-API-DMAC7.html) 2012-04-20 2015-08-07 Emergent Product Dev Seattle
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
EP2914628A1 (en) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Bcmaに対する抗体の選択のための方法
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
TW201506036A (zh) * 2013-08-14 2015-02-16 Laurantis Pharma Oy Vegf-c及ccbe1之治療用途
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
KR20240164967A (ko) 2014-02-04 2024-11-21 카이트 파마 인코포레이티드 B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
CN106456670B (zh) 2014-04-25 2020-01-07 蓝鸟生物公司 制备过继性细胞疗法的改善方法
WO2015164759A2 (en) 2014-04-25 2015-10-29 Bluebird Bio, Inc. Mnd promoter chimeric antigen receptors
BR112016024546A2 (pt) 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
US20170073415A1 (en) 2014-05-12 2017-03-16 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules
RS61406B1 (sr) 2014-06-06 2021-03-31 Bluebird Bio Inc Poboljšane kompozicije t ćelija
BR112017000939A2 (pt) 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Cd33キメラ抗原受容体を使用する癌の処置
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
CN113698497A (zh) 2014-12-05 2021-11-26 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
HRP20210582T1 (hr) 2014-12-05 2021-09-03 Memorial Sloan Kettering Cancer Center Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
US10647778B2 (en) 2015-02-09 2020-05-12 University Of Florida Research Foundation, Incorporated Bi-specific chimeric antigen receptor and uses thereof
EP3270960A4 (en) 2015-03-20 2018-08-08 Bluebird Bio, Inc. Vector formulations
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
TWI700298B (zh) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向b細胞成熟抗原之嵌合型抗原受體類
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
JP2018524373A (ja) 2015-07-15 2018-08-30 ザイムワークス,インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
CA2999070A1 (en) 2015-09-17 2017-03-23 Novartis Ag Car t cell therapies with enhanced efficacy
PT3393504T (pt) 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
WO2017190074A1 (en) * 2016-04-28 2017-11-02 The University Of Chicago Lymphangiogenesis for therapeutic immunomodulation
AU2017295704B2 (en) * 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
RU2019133286A (ru) 2017-03-22 2021-04-22 Новартис Аг Биомаркеры и средства терапии на основе т-клеток с car с повышенной эффективностью
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
KR20210093972A (ko) * 2018-11-16 2021-07-28 예일 유니버시티 뇌 및 cns 종양 요법을 위한 수막 림프계 맥관구조의 조작
US20220152150A1 (en) * 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
KR20220035910A (ko) * 2019-06-21 2022-03-22 노쓰 캐롤라이나 스테이트 유니버시티 Car-t 세포의 인시츄 모집, 재프로그래밍 및 방출

Similar Documents

Publication Publication Date Title
US11253547B2 (en) CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN113166262B (zh) Pd-1单结构域抗体及其治疗组合物
JP2023513003A (ja) Cd28シングルドメイン抗体ならびにその多価および多重特異性の構築物
JP2019537433A5 (cg-RX-API-DMAC7.html)
US20230028399A1 (en) Bcma-directed cellular immunotherapy compositions and methods
JP7646542B2 (ja) 新規アンタゴニスト抗tnfr2抗体分子
KR20230143177A (ko) 신규한 항-cd24 항체
KR20240032732A (ko) 암 면역요법을 위한 투약 요법
KR20240033025A (ko) Bcma-지시된 세포 면역요법 조성물 및 방법
KR20240039006A (ko) 신규 항-sirpa 항체
US20240400705A1 (en) Composition of recombinant antigen binding molecules and method of making and using thereof
JP2025524564A (ja) Cd19指向性がん免疫療法の投与レジメン
KR20240039005A (ko) 신규 다중-특이적 분자
WO2023036041A1 (zh) 抗4-1bb的激动型抗体及其应用
WO2025006631A1 (en) Dosing regimens for treatment of cancer
KR20240010020A (ko) 공동-자극 다중 특이성 항체
JP2025538424A (ja) 併用療法の投与レジメン
IT202100008201A1 (it) Frammento anticorpale della regione variabile a catena singola (scfv) e suo uso per la identificazione della porzione extracellulare del cd79b a scopo terapeutico e diagnostico
CA3171061A1 (en) Il2-based therapeutics and methods of use thereof
RU2019113504A (ru) Химерные антигенные рецепторы для лечения рака